Phosphatidylserine for Stress

Verdict: Weak, surrogate-only evidence for stress

Phosphatidylserine has only weak evidence for stress. A few very small trials show it can dampen the cortisol and ACTH surge triggered by exercise or acute stress, but these are short-term hormone readouts, not proof that it actually makes people feel less stressed.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The grade rests on just four small double-blind RCTs (n=8 to 75). Two older trials using brain-cortex PS blunted the exercise-induced ACTH and cortisol rise (PMID 1325348; PMID 2170852), and an industry-funded crossover trial of soy-derived PS cut plasma cortisol by about 39% around exercise (PMID 18662395). A larger industry-funded trial found a soy PS/phosphatidic-acid complex normalized the stress-hormone response, but only at the higher 400 mg dose and only in chronically high-stressed men; the 200 mg dose did nothing (PMID 25081826).

The core weakness is that almost every positive result is a surrogate endpoint, lower cortisol or ACTH, rather than a validated clinical outcome like perceived stress, anxiety, or quality of life. Samples are tiny, two of the key trials were funded by a supplement maker, and the oldest studies used a brain-cortex form that is no longer sold, so the findings transfer poorly to today's soy-based products.

Authorities do not back it for stress. European regulators (EFSA) reviewed and rejected the stress-reduction health claim, finding no established cause-and-effect, and no major clinic or specialty body (NIH ODS, Mayo, Cleveland Clinic, Harvard, the psychiatric and psychological associations) takes a supporting stance. That leaves a weak, cautiously worded verdict rather than a recommendation.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.46
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
79%
Broadly consistent
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L11 AI re-checkIndependent read
0.50
L5 Clinical bodiesAuthoritative stance
0.55
L2 PubMedPrimary literature
0.60
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.464
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Blunting by chronic phosphatidylserine administration of the stress-induced activation of the HPA axis in healthy men
PMID: 1325348 1992 RCT (double-blind) n = 9
Finding: PS significantly blunted exercise-induced ACTH (p=0.003) and cortisol (p=0.03) responses.
🟠 Limited quality
View on PubMed
Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans
PMID: 2170852 1990 RCT (double-blind) n = 8
Finding: Both 50mg and 75mg IV PS significantly blunted ACTH and cortisol responses to physical stress; no p-values in abstract.
🟠 Limited quality
View on PubMed
Effects of phosphatidylserine on the neuroendocrine and cortisol response to exercise (Starks et al.)
PMID: 18662395 2008 RCT (double-blind) n = 10
Finding: PS reduced plasma cortisol by 39% (p=0.03) and cortisol AUC by 35% (p<0.01) vs placebo.
🟠 Limited quality ⚠️ Industry-funded Effect size: Peak cortisol 26.9 vs 44.2 ug/dl (MD ~-17 ug/dl)
View on PubMed
A soy-based phosphatidylserine/phosphatidic acid complex (PAS) normalizes HPA stress reactivity in chronically stressed males
PMID: 25081826 2014 RCT (double-blind) n = 75
Finding: PAS 400 normalized ACTH (p=0.010), salivary (p=0.043) and serum cortisol (p=0.035) in chronically high-stressed subjects; PAS 200 not significant.
⚠️ Industry-funded
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4d TW TFDA / 衛福部
Neutral
訂定「食品原料磷脂醯絲胺酸(Phosphatidylserine)之使用限制」,並自中華民國一百十四年七月一日生效。 source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-stress-INT-phosphatidylserine-001 繁體中文版 →